Histamine and Pain: When Gut Mast Cells Fire Your Pain Nerves

She is fifty, and her list of safe foods has been shrinking for three years. She flushes after meals, abdominal pain lands within twenty minutes, loose stool follows, and her allergy tests are negative. Two physicians called it anxiety.

I’m Dr. Gurpreet Singh Padda, MD, MBA, MHP. Her case anchors the video She’s Not Allergic to Her Food. She’s Fermenting It., from The Angry Gut, which I wrote with Ami Michelle Grimes. For a pain practice the key point is simple: histamine and pain in the gut are joined by a cell, and that cell sits against a nerve.

Histamine and pain start with a cell pressed against a nerve

In biopsies from people with irritable bowel syndrome, 34 of 44 had more of the gut lining occupied by mast cells than controls, 9.2% of the surface against 3.3%. The count that tracked abdominal pain was not the total. It was the mast cells lying within five micrometers of a nerve, 7.14 per field in IBS against 2.27 in controls. Only those nerve-adjacent cells correlated with how severe and how frequent the pain was.

The chemistry fired nerves directly. Fluid from patients’ gut lining, applied to rat gut nerves, drove firing at 14.7 impulses per second against 2.8 for control fluid, and 64% of the responding neurons were capsaicin-sensitive pain fibers. It was human fluid on a rat nerve.

Here is the number a pain patient should notice. Blocking the histamine H1 receptor cut that nerve excitation by 51.7%. Inactivating the mast cell’s proteases cut it by 74.5%. Histamine is only one of the weapons, which helps explain why three antihistamines gave her about a third of the relief she needed and no more.

One event that gets treated as three problems

Mast cells are not stand-alone allergy cells. They sit where innate and adaptive immunity meet, respond to far more triggers than IgE, and signal back and forth with sensory nerve fibers. In the first brain, the gut, they are sentinels positioned downstream of the lymphocyte compartment, and their mediators drive both pain and a leaky lining. Histamine and proteases produce much of their pain effect through prostaglandins made inside the mast cell itself.

So her pain, her loose stool and her permeable gut wall are one process with three names, and each name got its own prescription. The second brain, the one in her skull, was checked for anxiety while the alarm kept ringing below.

Pain medicine has its own version of this. Some drugs fire mast cells directly through a receptor called MRGPRX2, with no antibody involved. Morphine, vancomycin, rocuronium and atracurium are among the named agents, and a negative allergy test does not clear them. Morphine’s itch, flushing and low blood pressure are poorly reversed by naloxone, and fentanyl, which lacks activity at that receptor, does not produce the same picture.

Where the gut’s histamine is really made

In a placebo-controlled challenge of patients referred for histamine intolerance, the diagnosis fell apart for most of them, and a majority reacted to the placebo. The source that holds up better is microbial.

Germ-free mice given stool from IBS patients with high urinary histamine developed visceral hypersensitivity and mast cell activation. Mice given stool from low-histamine patients did not. Blocking the histamine H4 receptor reversed it. In people with IBS, cutting fermentable carbohydrate lowered both pain and urinary histamine. Her bacteria were making histamine out of what she ate.

That shifts the job. Fermentable substrate comes down, overgrowth gets treated, and the gut wall gets repaired, the work of Chapter 29 on the gut barrier. Bacterial fragments crossing a leaky wall help keep the lining’s immune cells primed, a thread that starts in Chapter 4.

The incentives point the wrong way. An elimination list costs the system nothing to hand out, antihistamines refill indefinitely, and the hour it takes to learn why the cells are firing is the hour nobody reimburses.

What low-dose naltrexone does, link by link

Link one: the rebound. A brief opioid blockade prompts the body to raise its own endorphin. In human cerebrospinal fluid, naltrexone at a standard dose raised beta-endorphin from 1.15 to 2.03 fmol/mL while its precursor stayed flat, so the endorphin-to-precursor ratio rose 80%, and the effect held after two and seven days of treatment. That is human data, at a dose above the low-dose range.

Link two: the dose. Decades of laboratory work point to the duration of receptor blockade, not the size of the dose, as what decides the response. Intermittent blockade at low doses and continuous blockade at high doses pushed cell replication in opposite directions. At the full 100 mg dose naltrexone occupies 92% of kappa receptors, but nobody has measured occupancy at 1.5 to 4.5 mg in a living person. That gap is real.

Link three: lymphocytes and regulatory T cells. This is the least settled link. Whether human immune cells carry opioid receptors is contested. In female mice, regulatory T cells made their own enkephalin, which acted on delta opioid receptors on sensory neurons to restrain pain, a job separate from their immune suppression. What can be measured in people is output: after eight weeks of low-dose naltrexone in women with fibromyalgia, plasma levels of eighteen inflammatory mediators fell, including IL-1β, IL-6, IL-17A and TNF-α, and pain fell 15%. It was a small pilot, so read it as a signal.

Link four: TLR4. Naltrexone antagonizes Toll-like receptor 4, the sensor for bacterial lipopolysaccharide. In the defining cell-line experiment, every isomer tested, including the clinical one, blunted that signaling by non-competitive inhibition, though the animal work used other isomers. It is a weak antagonist, and no human study has shown low-dose naltrexone doing this. The tier is cellular and animal.

Why low-dose naltrexone is not a mast cell stabilizer

Naltrexone is inactive at MRGPRX2, the receptor opioids use to degranulate mast cells. In animal work it did not stop morphine-driven degranulation, while cromolyn, a true membrane stabilizer, did. Anyone describing low-dose naltrexone as a direct mast cell stabilizer has the pharmacology wrong.

The mechanism that survives is indirect and upstream. Rebound endorphin works on lymphocytes, including regulatory T cells. Blocking TLR4 reduces the cytokine load that keeps mucosal mast cells on a hair trigger. Quiet the signals that arm the sentinels and they fire less often, without the drug ever touching the mast cell membrane. For an earlier look at the drug in pain care, see low-dose naltrexone in intractable pain.

What the pain trials actually show

The randomized record in fibromyalgia is four trials and 222 patients, with a pooled pain reduction of 0.86 points and an improved pressure pain threshold on an algometer. The largest single trial, 6 mg for twelve weeks in women, missed its primary endpoint: pain fell 1.3 points on the drug and 0.9 on placebo. In IBS the only record is an open-label pilot at 0.5 mg daily, with global improvement in 76% of 42 patients. In a survey of 553 people with mast cell activation syndrome, self-rated benefit averaged 5.6 out of 10, the same as benzodiazepines, with antihistamines at 6.3.

That is a modest drug with a good safety record under 5 mg, and the tier should be explained to every patient plainly.

What changed for her, and what you can take from it

Her antihistamines stayed, as a bridge. The low-histamine list came off. Fermentable substrate came down, the overgrowth was treated, the barrier work began, and low-dose naltrexone started at 1.5 mg and was titrated. At five months she had added back nineteen foods and stopped flushing. That is one patient, not a trial, and individual results vary.

If your gut pain has been labeled stress, you can ask sharper questions. Has anyone looked at mast cells, not just allergy antibodies? Could a drug reaction in your history be the receptor-driven kind? Did the reactions begin after an antibiotic course, a gut infection or a surgery? Work any medication question through with your physician. Chapter 30 covers the daily maintenance underneath all of this, and Chapter 32 turns to the bowel that will not move at all. Every study above is laid out in the Chapter 31 Deep Dive, with the full numbers and what each trial does not show.

Frequently asked questions

Can histamine cause abdominal pain?

Yes, and not only through allergy. In irritable bowel syndrome, mast cells release histamine and proteases that directly excite pain-sensing nerves, and the cells lying closest to nerves track pain severity. Histamine accounts for part of that nerve firing and proteases for more. Read how pain-sensing neurons interact with gut inflammation.

Why don’t antihistamines fully stop gut pain?

They block one receptor while the cell keeps releasing everything else. In IBS tissue studies, blocking histamine H1 receptors cut nerve excitation by about half, while inactivating mast cell proteases cut it by more. Antihistamines can be a reasonable bridge, but the lasting work is finding out why the cells are firing and removing those triggers. Understand why a sensitized nervous system amplifies gut signals.

Is low-dose naltrexone a mast cell stabilizer?

No. Naltrexone is inactive at MRGPRX2, the receptor opioids use to trigger mast cells, and it did not block that degranulation in laboratory studies. Its proposed benefit runs upstream: a rebound rise in the body’s own endorphin acting on lymphocytes, and TLR4 antagonism that lowers the inflammatory signals keeping mast cells primed. The TLR4 link is cellular and animal evidence so far. See how low-dose naltrexone has been used for intractable pain.

Why can a drug reaction look like an allergy when allergy testing is negative?

Some drugs activate mast cells directly through a receptor called MRGPRX2, with no antibody and no prior sensitization. The reaction can look like allergy, with itching, flushing and a drop in blood pressure, yet there is nothing for an allergy test to find. Morphine, vancomycin, rocuronium and atracurium are among the agents named in that pathway. Find out whether a pain medication could be making pain worse.

Can gut bacteria make histamine that causes pain?

In mouse studies, yes. Germ-free mice colonized with stool from IBS patients with high urinary histamine developed gut pain hypersensitivity and mast cell activation, and blocking the histamine H4 receptor reversed it. In people with IBS, lowering fermentable carbohydrate reduced pain and urinary histamine together. The histamine that matters may be produced in the gut, not eaten. Learn what breath testing reveals about gut fermentation.

Sources

1. Barbara, G., Stanghellini, V., De Giorgio, R., Cremon, C., Cottrell, G. S., Santini, D., Pasquinelli, G., Morselli-Labate, A. M., Grady, E. F., Bunnett, N. W., Collins, S. M., & Corinaldesi, R. (2004). Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology, 126(3), 693-702. https://doi.org/10.1053/j.gastro.2003.11.055
2. Barbara, G., Wang, B., Stanghellini, V., de Giorgio, R., Cremon, C., Di Nardo, G., Trevisani, M., Campi, B., Geppetti, P., Tonini, M., Bunnett, N. W., Grundy, D., & Corinaldesi, R. (2007). Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome. Gastroenterology, 132(1), 26-37. https://doi.org/10.1053/j.gastro.2006.11.039
3. De Palma, G., Shimbori, C., Reed, D. E., Yu, Y., Rabbia, V., Lu, J., Jimenez-Vargas, N., Sessenwein, J., Lopez-Lopez, C., Pigrau, M., Jaramillo-Polanco, J., Zhang, Y., Baerg, L., Manzar, A., Pujo, J., Bai, X., Pinto-Sanchez, M. I., Caminero, A., Madsen, K., … Bercik, P. (2022). Histamine production by the gut microbiota induces visceral hyperalgesia through histamine 4 receptor signaling in mice. Science Translational Medicine, 14(655), eabj1895. https://doi.org/10.1126/scitranslmed.abj1895
4. Gordon, R. J., Panigrahi, S. K., Meece, K., Atalayer, D., Smiley, R., & Wardlaw, S. L. (2017). Effects of opioid antagonism on cerebrospinal fluid melanocortin peptides and cortisol levels in humans. Journal of the Endocrine Society, 1(10), 1235-1246. https://doi.org/10.1210/js.2017-00289
5. Midavaine, E., Moraes, B. C., Benitez, J., Rodriguez, S. R., Braz, J. M., Kochhar, N. P., Eckalbar, W. L., Tian, L., Domingos, A. I., Pintar, J. E., Basbaum, A. I., & Kashem, S. W. (2025). Meningeal regulatory T cells inhibit nociception in female mice. Science, 388(6742), 96-104. https://doi.org/10.1126/science.adq6531
6. Parkitny, L., & Younger, J. (2017). Reduced pro-inflammatory cytokines after eight weeks of low-dose naltrexone for fibromyalgia. Biomedicines, 5(2), 16. https://doi.org/10.3390/biomedicines5020016
7. Hutchinson, M. R., Zhang, Y., Brown, K., Coats, B. D., Shridhar, M., Sholar, P. W., Patel, S. J., Crysdale, N. Y., Harrison, J. A., Maier, S. F., Rice, K. C., & Watkins, L. R. (2008). Non-stereoselective reversal of neuropathic pain by naloxone and naltrexone: Involvement of toll-like receptor 4 (TLR4). The European Journal of Neuroscience, 28(1), 20-29. https://doi.org/10.1111/j.1460-9568.2008.06321.x
8. Lansu, K., Karpiak, J., Liu, J., Huang, X.-P., McCorvy, J. D., Kroeze, W. K., Che, T., Nagase, H., Carroll, F. I., Jin, J., Shoichet, B. K., & Roth, B. L. (2017). In silico design of novel probes for the atypical opioid receptor MRGPRX2. Nature Chemical Biology, 13(5), 529-536. https://doi.org/10.1038/nchembio.2334
9. Vatvani, A. D., Patel, P., Hariyanto, T. I., & Yanto, T. A. (2024). Efficacy and safety of low-dose naltrexone for the management of fibromyalgia: a systematic review and meta-analysis of randomized controlled trials with trial sequential analysis. The Korean Journal of Pain, 37(4), 367-378. https://doi.org/10.3344/kjp.24202
10. Weinstock, L. B., Afrin, L. B., Reiersen, A. M., Brook, J., Blitshteyn, S., Ehrlich, G., Schofield, J. R., Kinsella, L., Kaufman, D., Dempsey, T., & Molderings, G. J. (2025). Prevalence and treatment response of neuropsychiatric disorders in mast cell activation syndrome. Brain, Behavior, & Immunity – Health, 48, 101048. https://doi.org/10.1016/j.bbih.2025.101048

Medically reviewed by Dr. Gurpreet Singh Padda, MD, MBA, MHP, board certified in anesthesiology, pain medicine, interventional pain management, addiction medicine and obesity medicine. Adapted from Chapter 31 of The Angry Gut by Dr. Padda and Ami Michelle Grimes. Last reviewed September 2026.

Dr. Gurpreet Singh Padda, MD, MBA, MHP